Stay abreast of the latest advances from the academic thought leaders and expert clinicians of the Department of Psychiatry at Mount Sinai. Led by René Kahn, MD, PhD, our team is at the forefront of unlocking complex interactions between biological processes and the myriad states of the human mind. Ranked No. 6 among the nation's psychiatry departments for National Institute of Health funding, we are unrelenting in our commitment to advancing life-changing treatments. A vibrant community of psychiatric clinicians, researchers, educators, and trainees, our department is a national model for groundbreaking clinical research in neuropsychiatry, and our programs offer a wide range of diagnostic and treatment services for conditions ranging from addiction to major depression, autism, and schizophrenia.
Stay abreast of the latest advances from the academic thought leaders and expert clinicians of the Department of Psychiatry at Mount Sinai. Led by René Kahn, MD, PhD, our team is at the forefront of unlocking complex interactions between biological processes and the myriad states of the human mind. Ranked No. 6 among the nation's psychiatry departments for National Institute of Health funding, we are unrelenting in our commitment to advancing life-changing treatments. A vibrant community of psychiatric clinicians, researchers, educators, and trainees, our department is a national model for groundbreaking clinical research in neuropsychiatry, and our programs offer a wide range of diagnostic and treatment services for conditions ranging from addiction to major depression, autism, and schizophrenia.
Latest Videos
Video
How Epidemics Affect Our Mental Health
Craig Katz, MD, Director of Mount Sinai’s Global Mental Health Program, delivers a Grand Rounds presentation on the behavioral sequelae of epidemics.
Video
How to Use Psychological First Aid to Prevent Post-Disaster Psychopathology
Craig Katz, MD, Director of Mount Sinai’s Program in Global Mental Health, breaks down how to deliver psychological first aid in a disaster setting in order to prevent post-disaster psychopathology.
Video
STOP COVID NYC: A Study Capturing City-Wide Coronavirus Symptoms and Mental Health Impacts
Laura Huckins, PhD, Assistant Professor of Psychiatry, and Genetics and Genomic Sciences, discusses a new app-based survey gathering data on New York City residents and their COVID-19-related symptoms in order to better understand transmission ...
Video
CBD for Treating Opioid Addiction
Dr. Hurd’s latest study showed that CBD reduces cravings and anxiety in patients with heroin use disorder.
Video
Intergenerational Effects of Trauma: A Biological Perspective
Rachel Yehuda, PhD, discusses how trauma from previous generations can affect descendants from an epigenetic standpoint.
Video
New Frontiers for Depression: Deep Brain Stimulation, Esketamine, and the Immune System
“In five years, we expect to have a range of new treatments available targeting people with different forms of depression that work effectively, specifically for them.” –Eric Nestler, MD, PhD
Video
René Kahn, MD, PhD: Tackling the Neurobiology of Schizophrenia
Dr. Kahn discusses how brain changes in schizophrenic patients are related to disease progression and outcomes.
Video
An App-Based Game to Treat Depression
It looks and works like a game, but it acts like medicine—with no side effects.
Video
From Genes to Treatment: Using Rare Genetic Disorders to Develop Novel Therapeutics
Dr. Kolevzon’s talk at the Seaver Autism Center’s 21st Annual Advances in Autism Conference.
Video
The Mount Sinai Center for Stress, Resilience and Personal Growth
Mental health experts from Mount Sinai discuss the stress on front-line workers due to COVID-19 and the creation of the Center.
Latest Articles
News
Five Things to Know About Esketamine
In March 2019, intranasal esketamine—a form of ketamine marketed as SPRAVATO™ CIII Nasal Spray*—was approved by the U.S. Food and Drug Administration (FDA) to treat patients with treatment-resistant depression (TRD). James Murrough, MD, ...
News
Five Things to Know About MDMA-Assisted Psychotherapy for PTSD
MDMA, the psychoactive drug sometimes known as ecstasy, is poised to become a powerful tool in the treatment of PTSD. In 2017, the U.S. Food and Drug Administration (FDA) designated MDMA-assisted psychotherapy as a breakthrough therapy.
News
COVID-19 and Employee Mental Health: A Five-Tier Model of Support
New York City is an epicenter of COVID-19 pandemic in the United States, and the Mount Sinai Health System has spearheaded an array of clinical and organizational innovations to mitigate the crisis.
